company background image
EPIGRAL logo

Epigral NSEI:EPIGRAL Stock Report

Last Price

₹1.83k

Market Cap

₹79.5b

7D

-2.5%

1Y

76.3%

Updated

08 Jan, 2025

Data

Company Financials +

EPIGRAL Stock Overview

Manufactures and sells chlor-alkali and related derivatives in India and internationally. More details

EPIGRAL fundamental analysis
Snowflake Score
Valuation2/6
Future Growth4/6
Past Performance6/6
Financial Health3/6
Dividends3/6

My Notes

Capture your thoughts, links and company narrative

Epigral Limited Competitors

Price History & Performance

Summary of share price highs, lows and changes for Epigral
Historical stock prices
Current Share Price₹1,828.05
52 Week High₹2,406.75
52 Week Low₹931.60
Beta-0.10
1 Month Change-13.68%
3 Month Change-19.34%
1 Year Change76.33%
3 Year Change139.57%
5 Year Changen/a
Change since IPO349.76%

Recent News & Updates

Here's Why Epigral (NSE:EPIGRAL) Has Caught The Eye Of Investors

Dec 18
Here's Why Epigral (NSE:EPIGRAL) Has Caught The Eye Of Investors

Recent updates

Here's Why Epigral (NSE:EPIGRAL) Has Caught The Eye Of Investors

Dec 18
Here's Why Epigral (NSE:EPIGRAL) Has Caught The Eye Of Investors

Epigral Limited's (NSE:EPIGRAL) Shares Leap 29% Yet They're Still Not Telling The Full Story

Jul 04
Epigral Limited's (NSE:EPIGRAL) Shares Leap 29% Yet They're Still Not Telling The Full Story

Epigral Limited (NSE:EPIGRAL) Looks Just Right With A 27% Price Jump

Apr 19
Epigral Limited (NSE:EPIGRAL) Looks Just Right With A 27% Price Jump

Epigral Limited (NSE:EPIGRAL) Soars 28% But It's A Story Of Risk Vs Reward

Feb 23
Epigral Limited (NSE:EPIGRAL) Soars 28% But It's A Story Of Risk Vs Reward

Epigral (NSE:EPIGRAL) Might Be Having Difficulty Using Its Capital Effectively

Feb 21
Epigral (NSE:EPIGRAL) Might Be Having Difficulty Using Its Capital Effectively

Capital Investment Trends At Meghmani Finechem (NSE:MFL) Look Strong

Apr 05
Capital Investment Trends At Meghmani Finechem (NSE:MFL) Look Strong

With EPS Growth And More, Meghmani Finechem (NSE:MFL) Makes An Interesting Case

Sep 28
With EPS Growth And More, Meghmani Finechem (NSE:MFL) Makes An Interesting Case

Meghmani Finechem's (NSE:MFL) Promising Earnings May Rest On Soft Foundations

May 03
Meghmani Finechem's (NSE:MFL) Promising Earnings May Rest On Soft Foundations

Meghmani Finechem Limited's (NSE:MFL) Business Is Yet to Catch Up With Its Share Price

Nov 22
Meghmani Finechem Limited's (NSE:MFL) Business Is Yet to Catch Up With Its Share Price

Shareholder Returns

EPIGRALIN ChemicalsIN Market
7D-2.5%0.2%-0.07%
1Y76.3%3.6%16.0%

Return vs Industry: EPIGRAL exceeded the Indian Chemicals industry which returned 3.6% over the past year.

Return vs Market: EPIGRAL exceeded the Indian Market which returned 16% over the past year.

Price Volatility

Is EPIGRAL's price volatile compared to industry and market?
EPIGRAL volatility
EPIGRAL Average Weekly Movement6.5%
Chemicals Industry Average Movement5.9%
Market Average Movement6.2%
10% most volatile stocks in IN Market9.0%
10% least volatile stocks in IN Market4.1%

Stable Share Price: EPIGRAL has not had significant price volatility in the past 3 months compared to the Indian market.

Volatility Over Time: EPIGRAL's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2007997Kaushal Soparkarwww.epigral.com

Epigral Limited manufactures and sells chlor-alkali and related derivatives in India and internationally. The company offers chlorinated polyvinyl chloride (CPVC) resins, epichlorohydrin, chloromethanes value chain, hydrogen peroxide, caustic soda, chlorine, hydrogen, and caustic potash products. It also engages in the trading of agrochemical products.

Epigral Limited Fundamentals Summary

How do Epigral's earnings and revenue compare to its market cap?
EPIGRAL fundamental statistics
Market cap₹79.55b
Earnings (TTM)₹2.94b
Revenue (TTM)₹22.73b

26.9x

P/E Ratio

3.5x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
EPIGRAL income statement (TTM)
Revenue₹22.73b
Cost of Revenue₹13.19b
Gross Profit₹9.55b
Other Expenses₹6.61b
Earnings₹2.94b

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)68.04
Gross Margin42.00%
Net Profit Margin12.91%
Debt/Equity Ratio63.9%

How did EPIGRAL perform over the long term?

See historical performance and comparison

Dividends

0.3%

Current Dividend Yield

11%

Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/08 17:05
End of Day Share Price 2025/01/08 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Epigral Limited is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullBP Wealth Management Private Limited
Meet VoraEmkay Global Financial Services Ltd.
Kameswari V. S. ChavaliFirstCall Research